Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SMMT
STRONG SELLSummit Therapeutics Inc. · Healthcare · United States · $10.9B · Avg Vol: $64M/d
COMPANY DESCRIPTION
Summit Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing novel medicines for serious infectious diseases and oncology. The company's pipeline includes late-stage clinical candidates, particularly in treating multi-drug resistant infections and cancer. It leverages strategic partnerships and R&D efforts to address significant unmet medical needs in challenging therapeutic areas.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.7M | 0 | 0 | 0 | — | — | 2.4M | 44.1M | 128.7% |
| EPS | -0.11 | -0.99 | -0.31 | -1.44 | — | -1.59 | -0.86 | -0.89 | — |
| Shares | 776.2M | 701.7M | 737.6M | 775.4M | -0.1% | 776.2M | — | — | — |
| Debt | 518.8M | 106.1M | 7.2M | 20.9M | -65.7% | 20.0M | — | — | — |
| Equity | 126.7M | 77.7M | 388.7M | 658.9M | 73.3% | — | — | — | — |
| Op CF | -41.6M | -76.8M | -142.1M | -322.9M | — | -384.1M | — | — | — |
| Inv CF | -0.6M | -587.8M | -205.3M | -174.3M | — | — | — | — | — |
| Fin CF | 620.2M | 86.5M | 381.2M | 617.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SMMT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SMMT | Summit Therapeutics Inc.(you) | $10.9B | 9 | STRONG SELL |
| IONS | Ionis Pharmaceuticals, Inc. | $9.3B | 6 | STRONG SELL |
| 0JAV.L | Insmed Incorporated | $18.9B | 9 | STRONG SELL |
| CYTK | Cytokinetics, Incorporated | $11.0B | 26 | SELL |
| MANE | Veradermics, Incorporated | $4.6B | 8 | STRONG SELL |
| SRRK | Scholar Rock Holding Corporation | $5.7B | 15 | STRONG SELL |
| KYMR | Kymera Therapeutics, Inc. | $9.1B | 25 | SELL |
| PRAX | Praxis Precision Medicines, Inc. | $9.1B | 28 | SELL |
| NUVL | Nuvalent, Inc. | $9.8B | 30 | SELL |
| CELC | Celcuity Inc. | $4.0B | 14 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%